Cargando…

Preoperative Cancer Antigen 125 Level as Predictor for Complete Cytoreduction in Ovarian Cancer: A Prospective Cohort Study and Systematic Review

SIMPLE SUMMARY: Standard treatment of advanced stage epithelial ovarian cancer consists of cytoreductive surgery (CRS) and chemotherapy. Prolonged progression free and overall survival is correlated with the amount of residual tumor after CRS. However, cytoreductive surgery is an extensive procedure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brons, Puck E., Nieuwenhuyzen-de Boer, Gatske M., Ramakers, Christian, Willemsen, Sten, Kengsakul, Malika, van Beekhuizen, Heleen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740757/ https://www.ncbi.nlm.nih.gov/pubmed/36497218 http://dx.doi.org/10.3390/cancers14235734

Ejemplares similares

Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis
por: Kengsakul, Malika, et al.
Publicado: (2022)

Factors Predicting 30-Day Grade IIIa–V Clavien–Dindo Classification Complications and Delayed Chemotherapy Initiation after Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Prospective Cohort Study
por: Kengsakul, Malika, et al.
Publicado: (2022)

Survival in Advanced-Stage Epithelial Ovarian Cancer Patients with Cardiophrenic Lymphadenopathy Who Underwent Cytoreductive Surgery: A Systematic Review and Meta-Analysis
por: Kengsakul, Malika, et al.
Publicado: (2021)

Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study
por: Nieuwenhuyzen-de Boer, Gatske M., et al.
Publicado: (2022)

Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients
por: Nieuwenhuyzen-de Boer, Gatske M., et al.
Publicado: (2023)

ASO Author Reflections: The PlasmaJet(®) Device Contributes to an Increase in the Number of Complete Cytoreductive Surgeries for Ovarian Cancer Patients
por: Nieuwenhuyzen-de Boer, G. M., et al.
Publicado: (2022)

Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review
por: Nieuwenhuyzen-de Boer, Gatske M., et al.
Publicado: (2019)

The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series
por: Nieuwenhuyzen-de Boer, Gatske M., et al.
Publicado: (2022)

Plasma Device Functions and Tissue Effects in the Female Pelvis—A Systematic Review
por: van de Berg, Nick J., et al.
Publicado: (2023)

Hyperspectral Imaging for Tissue Classification after Advanced Stage Ovarian Cancer Surgery—A Pilot Study
por: van Vliet-Pérez, Sharline M., et al.
Publicado: (2022)

Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction
por: Koirala, Pratistha, et al.
Publicado: (2020)

Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
por: Merlo, Sebastjan, et al.
Publicado: (2021)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
por: Winarno, G. N. A., et al.
Publicado: (2020)

Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands
por: Nieuwenhuyzen-de Boer, G. M., et al.
Publicado: (2022)

Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
por: Mousavi, Azam-Sadat, et al.
Publicado: (2010)

The Significance of Preoperative Computed Tomography for Predicting Optimal Cytoreduction in Advanced Ovarian Cancer
por: Stachs, Angrit, et al.
Publicado: (2020)

Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
por: Feng, Li-yuan, et al.
Publicado: (2020)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Worldwide initiatives to eliminate cervical cancer
por: Wilailak, Sarikapan, et al.
Publicado: (2021)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas
por: Choi, Ji Hui, et al.
Publicado: (2018)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis
por: Hu, Ting Wen Yi, et al.
Publicado: (2018)

Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases
por: Khaled, Charif, et al.
Publicado: (2023)

Laparoscopic Cytoreduction for Primary Advanced Ovarian Cancer
por: Fanning, James, et al.
Publicado: (2010)

CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
por: Wang, Fang, et al.
Publicado: (2013)

Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
por: Hopkins, M.L., et al.
Publicado: (2007)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer
por: Eo, Wankyu, et al.
Publicado: (2016)

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)
por: DOGAN, NASUH UTKU, et al.
Publicado: (2013)

Role of aggressive surgical cytoreduction in advanced ovarian cancer
por: Chang, Suk-Joon, et al.
Publicado: (2015)

Splenectomy during cytoreductive surgery in epithelial ovarian cancer
por: Sun, Hengzi, et al.
Publicado: (2018)

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer
por: Luna-Abanto, Jorge, et al.
Publicado: (2020)

Trends in extent of surgical cytoreduction for patients with ovarian cancer
por: Wong, Deanna H., et al.
Publicado: (2021)

Predicting incomplete cytoreduction in patients with advanced ovarian cancer
por: Egger, Eva K., et al.
Publicado: (2022)

Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2023)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index
por: Llueca, Antoni, et al.
Publicado: (2018)

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors
por: Winarno, Gatot Nyarumenteng Adhipurnawan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sib5sna5m4lbn82o4e8pdvsrtd